Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ORPHENADRINE vs OSIMERTINIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

ORPHENADRINE vs OSIMERTINIB: Safety Overview

Metric ORPHENADRINE OSIMERTINIB
Total FAERS Reports 584 27,750
Deaths Reported 121 12,456
Death Rate 20.7% 44.9%
Hospitalizations 159 5,277
Average Patient Age 47.9 yrs 68.2 yrs
% Female Patients 79.3% 66.0%
FDA Approval Date Approved Prior to Jan 1, 1982 Nov 13, 2015
Manufacturer Sandoz Inc AstraZeneca Pharmaceuticals LP
Route ORAL ORAL
Marketing Status Discontinued Prescription